Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Https://www.nasdaq.com/market-activity/stocks/tlsa/press-releases
hi , is there a link to a recording anyone could share on here please ?
B.Riley Financial Keeps Their Buy Rating on Tiziana Life Sciences (TLSA)
10/03/2022 3:55pm
TipRanks
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Tiziana Life Sciences (TLSA – Research Report), with a price target of $3.00. The company's shares closed last Thursday at $0.93, close to its 52-week low of $0.53. According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.0% and a 25.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. Tiziana Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
https://www.tipranks.com/news/blurbs/b-riley-financial-keeps-their-buy-rating-on-tiziana-life-sciences-tlsa-2?utm_source=advfn.com&utm_medium=referral
Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapy
Data show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET) along with downregulation of pro-inflammatory cytokines associated with brain inflammation, as well as stabilization of disease as measured by clinical assessments
Based on these observations the FDA has allowed a second patient to receive intranasal foralumab therapy under a separate Single-Patient Expanded Access IND (SPIND)
Tiziana to hold Key Opinion Leader (KOL) event to discuss the data on March 14th, 2022, 11 a.m. ET